Build story
Cipla's affordable access strategy in global medicine
A pharmaceutical company made a strategic decision to produce and sell life-saving medication at a small fraction of the price charged elsewhere, dramatically expanding access in price-sensitive markets.
In the early 2000s, life-saving antiretroviral medication for a major global health crisis was priced by international pharmaceutical companies at a level that made it inaccessible to the vast majority of patients in developing countries, despite the urgent and widespread need.
This Indian pharmaceutical company's leadership made a deliberate strategic decision to manufacture generic versions of the needed combination therapy and offer it at a price dramatically lower than the prevailing international price — a fraction of what was being charged elsewhere at the time.
This move drew significant international attention and controversy, including legal and diplomatic pressure, but also fundamentally shifted the global conversation about medicine pricing and access in developing markets, contributing to broader international efforts to expand affordable access to essential medication.
The company built a lasting reputation and business position around affordable, accessible medicine, demonstrating that a lower-price strategy in a life-critical category could be both a genuine public health contribution and a viable long-term business model, given sufficient manufacturing scale.
the lesson
In categories where affordability is a genuine barrier to access, an aggressive low-cost strategy can open an enormous underserved market while making a real difference — provided the underlying manufacturing scale and quality can sustain it.